Compare CAL & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAL | XFOR |
|---|---|---|
| Founded | 1878 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.0M | 377.3M |
| IPO Year | 1994 | 2017 |
| Metric | CAL | XFOR |
|---|---|---|
| Price | $12.45 | $2.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $17.00 | $11.60 |
| AVG Volume (30 Days) | 539.7K | ★ 1.2M |
| Earning Date | 09-09-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.14 | N/A |
| Revenue | ★ $85,513,000.00 | $6,500,000.00 |
| Revenue This Year | $3.87 | N/A |
| Revenue Next Year | $2.84 | N/A |
| P/E Ratio | $5.72 | ★ N/A |
| Revenue Growth | 0.46 | ★ 150.00 |
| 52 Week Low | $8.80 | $2.73 |
| 52 Week High | $15.04 | $4.83 |
| Indicator | CAL | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 49.95 | 24.21 |
| Support Level | $12.02 | N/A |
| Resistance Level | $14.20 | $4.45 |
| Average True Range (ATR) | 0.50 | 0.18 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 69.11 | 0.53 |
Caleres Inc is a footwear company that operates retail shoe stores and e-commerce websites, and designs, develops, sources, manufactures, and distributes footwear for people of all ages. The Company's business operations are organized into two reportable segments - Famous Footwear and Brand Portfolio. The Famous Footwear segment is comprised of its Famous Footwear retail stores, famousfootwear.com, and famousfootwear.ca. The Brand Portfolio segment offers retailers and consumers a cultivated portfolio of known brands. This segment is comprised of wholesale operations that designs, develops, sources, manufactures, markets and distributes branded, licensed and private-label footwear. Geographically, the company generates the majority of its revenue from Domestic operations.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.